SLS - ガリ―ナ・バイオファ―マ （SELLAS Life Sciences Group Inc. ）

The share price of SELLAS Life Sciences Group Inc. (NASDAQ:SLS) rose to $2.46 per share on Wednesday from $2.42. While SELLAS Life Sciences Group Inc. has overperformed by 1.65%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SLS fell by -63.93%, with highs and lows ranging […]

At the close of the New York Stock Exchange, the Dow Jones fell 0.63%, the S&P 500 fell 0.89%, and the NASDAQ Composite index fell 1.12%. Merck & Company Inc was the top gainer among the components of the Dow Jones index today, up 2.39 points or 2.44% to close at 100.35. Quotes of Johnson & Johnson rose by 2.66 points (1.57%), ending trading at 171.91. Visa Inc Class A rose 1.86 points or 0.91% to close at 206.86. The least gainers were Walmart Inc, which shed 4.19 points or 2.94% to end the session at 138.39. Home Depot Inc was up 2.55% or 8.02 points to close at 306.92 while Dow Inc was down 2.24% or 1.19 points to close at 51. 95. Leading gainers among the components of the S&P 500 in today''s trading were CF Industries Holdings Inc, which rose 5.21% to hit 107.76, PENN Entertainment Inc, which gained 4.59% to close at 37.63. as well as Moderna Inc, which rose 4.57% to close the session at 179.03. The least gainers were Hasbro Inc, which shed 9.86% to close at 57.16. Shares of Bath & Body Works Inc. lost 8.17% and ended the session at 33.06.

SELLAS Life Sciences Group Inc (NASDAQ: SLS ) announced updates relating to its ongoing Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients who have achieved complete remission following second-line salvage therapy (CR2 patients). A review of preliminary data suggests that the median overall survival (OS) in the pooled study population is likely considerably longer, by approximately two-fold, than initially anticipated and upon which the statistical analysis plan was based. Related:

Shares of SELLAS Life Sciences Group (NASDAQ: SLS) were in a downward spiral on Monday morning as the late-stage clinical biopharmaceutical company announced a business update. SELLAS announced that it was postponing the interim analysis of its Phase 3 registrational clinical trial for its lead asset galinpepimut-S (GPS) to late next year or early 2024 from its earlier timeline of early next year. GPS is the company''s novel therapy used in the treatment of patients with acute myeloid leukemia (AML).

Opiant Pharmaceuticals OPNT +113%. Ardelyx (ARDX) +40%. Satsuma Pharmaceuticals STSA -81%. Sellas Life Sciences SLS -37%.

NEW YORK , Oct. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDO, KAVL, T, SLS, and LBRT. … Full story available on Benzinga.com

The following slide deck was published by SELLAS Life Sciences Group, Inc.

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS ) ("SELLAS'''' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the election of Katherine Bach Kalin to its Board of Directors. "We are delighted to welcome someone with the breadth and depth of industry experience as Katherine has to join our Board of Directors," stated Jane Wasman, Chair of the Board of SELLAS. "Having spent her career working in strategy, business development, sales and marketing, and finance within the life sciences and healthcare industries, Katherine will be a valuable addition to the SELLAS team as the Company continues to evolve and grow," said Ms. Wasman. Ms. Kalin''s healthcare industry experience spans pharmaceuticals, diagnostics, medical devices and digital health. She currently serves as a non-executive director on the boards of Genfit S.A., a French, public biopharmaceutical company, where she serves on the Strategy and Alliances Committee, and two private companies, Brown Advisory LLC, an independent investment and strategic advisory firm, where she sits on the Audit and Finance Committees, and FemHealth Ventures, a venture capital firm that seeks to invest in women''s health.

https://www.investing.com/news/pro/sellas-life-sciences-group-pt-lowered-to-8-at-ladenburg-thalmann-432SI-2872395

The following slide deck was published by SELLAS Life Sciences Group, Inc.

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS ) ("SELLAS'''' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the election of Katherine Bach Kalin to its Board of Directors. "We are delighted to welcome someone with the breadth and depth of industry experience as Katherine has to join our Board of Directors," stated Jane Wasman, Chair of the Board of SELLAS. "Having spent her career working in strategy, business development, sales and marketing, and finance within the life sciences and healthcare industries, Katherine will be a valuable addition to the SELLAS team as the Company continues to evolve and grow," said Ms. Wasman. Ms. Kalin''s healthcare industry experience spans pharmaceuticals, diagnostics, medical devices and digital health. She currently serves as a non-executive director on the boards of Genfit S.A., a French, public biopharmaceutical company, where she serves on the Strategy and Alliances Committee, and two private companies, Brown Advisory LLC, an independent investment and strategic advisory firm, where she sits on the Audit and Finance Committees, and FemHealth Ventures, a venture capital firm that seeks to invest in women''s health.

https://www.investing.com/news/pro/sellas-life-sciences-group-pt-lowered-to-8-at-ladenburg-thalmann-432SI-2872395

SELLAS Life Sciences press release (SLS): Q2 GAAP EPS of -$0.41 misses by $0.02.As of June 30, 2022, cash and cash equivalents totaled approximately $27M.